SUBSCRIBE
SUBSCRIBE
Greg Slabodkin

Greg Slabodkin

Greg is a seasoned editor/writer who has covered the healthcare, life sciences and medical device industries for several tech trade publications. He is the recipient of a Post-Newsweek Business Information Editorial Excellence Award for his news reporting and a Gold Award for Best Case Study from the American Society of Healthcare Publication Editors. In addition, Greg is a Healthcare Fellow from the Society for Advancing Business Editing and Writing. He is an avid Buffalo Bills football fan, likes to kayak and plays guitar.

Business
Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway
Merck and Novartis beat expectations this week with solid third-quarter financial results, while BMS, Sanofi and Takeda spooked investors with negative near- and mid-term projections.
October 27, 2023
 · 
2 min read
 · 
Greg Slabodkin
Pictured: 3D illustration of antibody-drug conjugates with their toxic payloads
Business
Biopharma Industry Continues to Bet Big on Antibody-Drug Conjugates
While Merck lost out to Pfizer earlier this year in snapping up Seagen, this week the company closed a deal worth a potential $22 billion with Daiichi Sankyo—further evidence of the industry’s insatiable appetite for ADC technology.
October 20, 2023
 · 
2 min read
 · 
Greg Slabodkin
Pictured: American cash shaped into a funnel/iStoc
Deals
Early October Sees Torrid Pace of Biotech M&A—Will It Continue?
The first two weeks of October saw BMS’s $4.8 billion buyout of Mirati, Lilly’s $1.4 billion purchase of Point, Kyowa Kirin’s $387 million acquisition of Orchard and AbbVie’s $110 million Mitokinin deal.
October 13, 2023
 · 
2 min read
 · 
Greg Slabodkin
Pictured: Boardroom overlooking a city/iStock, ism
Drug Development
Amgen and US WorldMeds: A Tale of Data and Two FDA Adcomm Meetings
Though data became an issue in two separate meetings, the FDA’s Oncologic Drugs Advisory Committee made a potentially precedent-setting decision by voting in favor of US WorldMeds’ neuroblastoma treatment.
October 6, 2023
 · 
2 min read
 · 
Greg Slabodkin
Pictured: Boy in orange shirt on a wheelchair at t
Business
Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on Horizon
An FDA advisory committee this week voted overwhelmingly against BrainStorm Cell Therapeutics’ amyotrophic lateral sclerosis treatment. However, other potential therapies offer hope for ALS patients.
September 29, 2023
 · 
2 min read
 · 
Greg Slabodkin
Pictured: Stop sign in front of FDA headquarters/S
Drug Development
FDA Regulatory Gauntlet Isn’t Getting Any Easier, Just Ask These Companies
ARS Pharmaceuticals, Intarcia Therapeutics and Taysha Gene Therapies this week got stark reminders of the difficulties in getting treatments through the regulator’s approval process.
September 22, 2023
 · 
2 min read
 · 
Greg Slabodkin
Pictured: Series of outcroppings with steep cliffs
Drug Development
Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?
In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.
September 15, 2023
 · 
2 min read
 · 
Greg Slabodkin
Pictured: Hand changing blocks from Plan A to B/iS
Business
Week in Review: Astellas Withdraws IRA Lawsuit, New Illumina CEO and More
After its prostate cancer therapy was not included in Medicare’s initial drug price negotiation list, Astellas dismissed its Inflation Reduction Act lawsuit this week, while Illumina got new leadership.
September 8, 2023
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Federal Trade Commission Sign/Courtesy o
Business
Week in Review: Amgen-Horizon Deal Moves Forward, First 10 Drugs for IRA Price Negotiation, Layoffs and More
$27.8B Amgen-Horizon deal gets FTC clearance with restrictions; the White House names first 10 drugs subject to Medicare price negotiations; Sage Therapeutics axes 40% of staff.
September 1, 2023
 · 
2 min read
 · 
Greg Slabodkin
Pictured: An elderly man with his hand over his he
Drug Development
Week in Review: Wegovy’s Cardio Benefits, Biosimilars Gather Momentum and More
A second trial shows Novo Nordisk’s Wegovy improves heart health. Meanwhile, many other drugs are beginning to face generic competition, including from newly approved biosimilars.
August 25, 2023
 · 
2 min read
 · 
Greg Slabodkin
Pictured: Facade of Moderna's building in Massachusetts
Business
Moderna, CARsgen Join Forces Combining mRNA Cancer Vaccine with CAR T
The companies will evaluate Moderna’s investigational Claudin18.2 mRNA cancer vaccine in combination with CARsgen’s Claudin18.2 CAR T cell candidate.
August 21, 2023
 · 
2 min read
 · 
Greg Slabodkin
Pictured: a scale and tape measure_iStock, Tatiana
Drug Development
Week in Review: Obesity Drug Race, Ipsen Therapy Finally Gets Approval and More
Boehringer Ingelheim will launch three Phase III studies for its obesity drug candidate; third time is a charm for Ipsen as it gets FDA approval; and Pfizer takes multiple myeloma battle to J&J.
August 18, 2023
 · 
2 min read
 · 
Greg Slabodkin
A Novo Nordisk flag flies in the wind/Courtesy jor
Business
Week in Review: Novo Nordisk Riding High, Novavax in the Black (For Now), Nektar Sues Lilly and More
Novo’s weight-loss drug Wegovy improves cardiovascular outcomes, Novavax posts surprise Q2 profit, while Nektar Therapeutics files lawsuit against Eli Lilly for misconduct in drug development deal.
August 11, 2023
 · 
2 min read
 · 
Greg Slabodkin
Pictured: A man in a suit examines drugs with a ma
Business
Week in Review: Breakthrough Depression Drug, RSV and GLP-1 Lawsuits, and Earnings Season Shows COVID Cliff
A transformational moment in the treatment of depression, GSK takes first shot in a vaccine patent war with Pfizer, a Louisiana woman sues Novo Nordisk and Lilly, and companies face a steep COVID-19 cliff.
August 4, 2023
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Businessmen shaking hands after closing a deal
Drug Development
Week in Review: Biogen M&A and Layoffs, Earnings Season Heats Up, and 12 Neuro Companies to Watch
Biogen’s $7.3 billion Reata acquisition and layoffs dominated this week’s news, while BMS and Roche reported second-quarter earnings and BioSpace looked at 12 late-stage neuro companies.
July 28, 2023
 · 
2 min read
 · 
Greg Slabodkin
Load More